Riitta Lassila on LMWH Benefits in COVID19
Riitta Lassila, Professor of Coagulation Medicine at University of Helsinki, shared on LinkedIn:
”We are happy to report RDW benefits from early high risk (the same for corona disease progression and thrombosis) – targeted LMWH prophylaxis initiated at outpatient setting.
The two first virus waves when vaccination program had only started.
Lessons for any future severe viral outbursts.”
Read the full article here.
Article: Early outpatient use of low-molecular-weight heparin benefits COVID-19 outcome in association with hospitalization – Lessons learned
Authors: Miika Koskinen, Eeva Ruotsalainen, Mia Wallin, Hilkka Kivelä, Kerstin Carlsson, Jari Petäjä, Eero Hirvensalo, Markku Mäkijärvi, Riitta Lassila

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders
-
Nov 13, 2026, 16:17Shailendra Singh: Bombay Hospital Jaipur Inaugurates New Facility with Voluntary Blood Donation Camp
-
Nov 13, 2026, 16:10Minka Zivkovic: UMC Utrecht Announces Research Analyst Vacancy in Thrombosis and Haemostasis
-
Nov 13, 2026, 16:02Rounak Dubey: Elsevier’s Upcoming Handbook Explores Digitalization in Transfusion Medicine
-
Nov 13, 2026, 15:50Maha Othman: CanVECTOR 2026 Highlights Research on Immunothrombosis and Cancer-Associated Thrombosis